Evidence map›Paper›PMID 28825656›Full record

ArticleJournal of clinical medicine2017

Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice.

Alireza Morovat, Gayani Weerasinghe, Victoria Nesbitt, Monika Hofer, Thomas Agnew, Geralrine Quaghebeur, Kate Sergeant, Carl Fratter, Nishan Guha, Mehdi Mirzazadeh and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Biomarkers of mitochondrial disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  13. A clinical approach to diagnosis and management of mitochondrial myopathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  14. Article
  15. Article
  16. Red Flags in Primary Mitochondrial Diseases: What Should We Recognize?International journal of molecular sciences · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Alireza MorovatDepartment of Clinical Biochemistry, Oxford University Hospitals, Oxford OX3 9DU, UK. reza.morovat@ouh.nhs.uk.
Gayani WeerasingheDepartment of Clinical Biochemistry, Oxford University Hospitals, Oxford OX3 9DU, UK. gayani.weerasinghe@ouh.nhs.uk.
Victoria NesbittDepartment of Paediatrics, The Children's Hospital, Oxford OX3 9DU, UK. victoria.nesbitt@ouh.nhs.uk.
Monika HoferDepartment of Neuropathology and Ocular Pathology, West Wing, Oxford University Hospitals, Oxford OX3 9DU, UK. monika.hofer@ouh.nhs.uk.
Thomas AgnewSir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK. thomas.agnew@path.ox.ac.uk.
Geralrine QuaghebeurDepartment of Neuroradiology, West Wing, Oxford University Hospitals, Oxford OX3 9DU, UK. gerardine.quaghebeur@ouh.nhs.uk.
Kate SergeantNHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford Medical Genetics Laboratories, Oxford University Hospitals, Oxford OX3 7LE, UK. kate.sergeant@ouh.nhs.uk.
Carl FratterNHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford Medical Genetics Laboratories, Oxford University Hospitals, Oxford OX3 7LE, UK. carl.fratter@ouh.nhs.uk.
Nishan GuhaDepartment of Clinical Biochemistry, Oxford University Hospitals, Oxford OX3 9DU, UK. nishan.guha@ouh.nhs.uk.
Mehdi MirzazadehDepartment of Clinical Biochemistry, Oxford University Hospitals, Oxford OX3 9DU, UK. mehdi.mirzazadeh@nhs.net.
Joanna PoultonNuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford OX3 9DU, UK. joanna.poulton@obs-gyn.ox.ac.uk.
Oxford University Hospitals NHS Trust · GBUniversity of Oxford · GBJohn Radcliffe Hospital · GB

Funding

Medical Research Council G0800674Medical Research Council MR/J010448/1
6 · The paper itself

Abstract

Recent work has suggested that fibroblast growth factor-21 (FGF-21) is a useful biomarker of mitochondrial disease (MD). We routinely measured FGF-21 levels on patients who were investigated at our centre for MD and evaluated its diagnostic performance based on detailed genetic and other laboratory findings. Patients' FGF-21 results were assessed by the use of age-adjusted

Indexed as

diagnosisFGF-21fibroblast growth factor-21mitochondrial disease

Identifiers

PMID28825656
PMCPMC5575582
OpenAlexW2749381405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.